Management tracks: Real Endpoints, Poxel, Travecta

Reimbursement consultancy Real Endpoints LLC hired Jeff Berkowitz as CEO. He replaces Roger Longman who becomes chairman. Berkowitz was EVP at UnitedHealth Group Inc. (NYSE:UNH), where he was CEO of its Optum International business and strategic leader of its PBM, OptumRx.

Metabolic disease company Poxel S.A. (Euronext:POXEL) hired Takashi Kaneko as SVP of medical and president of its Poxel Japan K.K. subsidiary. He was head of medical affairs for the Japanese unit of the Janssen Pharmaceuticals K.K. subsidiary of Johnson & Johnson (NYSE:JNJ).

Blood-brain barrier delivery company Travecta Therapeutics Pte. Ltd. (Singapore) hired Douglas Hicks as CBO. He was SVP of business development and strategy at iBio Inc. (NYSE-M:IBIO).

Travecta launched this year with a license from Duke-NUS Medical School to IP from the lab of David Silver, who discovered a major facilitator superfamily domain containing 2A (MFSD2A; MFSD2)-directed drug delivery platform. Silver co-founded the company, along with Michael Schleifer and Laurent Benissan from health science consultancy firm Sprim, with funds from Tikehau Capital.